No Data
Jiuman Gene (02566) will distribute a final dividend of 0.56 yuan for every 10 shares on July 30.
Jiu Yuan Gene (02566) announced that the company will distribute a final dividend of every 10 shares on July 30, 2025...
JIUYUAN GENE: 2024 ANNUAL REPORT
Jiuyuan Gene (02566) has completed the registration procedures for the name change, and the new name is officially effective.
JiuYuan Gene (02566) announced that following the approval of the change of the company's name by the shareholders through a special resolution, as of...
Jiuyuan Gene (02566) has released its first performance announcement after being上市. In 2024, it is expected to achieve a revenue of 1.369 billion yuan, with a compound growth rate of over 33% for orthopedic products.
On March 26, Jiuyuan Gene (02566) announced its first annual performance report after going public.
Jiuyuan Gene (02566.HK) reported 1.369 billion yuan in revenue for 2024, an increase of 6.4% year-on-year.
Gelonghui, March 26丨Jiuyuan Gene (02566.HK) announced that for the financial year ending December 31, 2024, the annual performance showed a revenue of 1.369 billion yuan, a year-on-year increase of 6.4%. The profit attributable to the company's owners for the year was 0.139 billion yuan, an increase of 18.8 million yuan compared to 0.12 billion yuan in 2023. The basic earnings per share were approximately 0.68 yuan, up from 0.60 yuan in 2023. The revenue from biopharmaceutical (device) products was 1.077 billion yuan, accounting for over 78% of total revenue. Among them, the revenue from orthopedic products saw a year-on-year growth of over.
Hangzhou Jiuyuan Gene Engineering Reports Strong 2024 Financial Results
